The potential role of microRNAs in lung allograft rejection

被引:17
|
作者
Ladak, Shameem S. [1 ]
Ward, Chris [1 ]
Ali, Simi [1 ]
机构
[1] Newcastle Univ, Sch Med, Inst Cellular Med, Framlington Pl,Third Floor,William Leech Bldg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
来源
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2016年 / 35卷 / 05期
关键词
microRNA; biomarkers; allograft rejection; BOS; fibrosis; EPITHELIAL-MESENCHYMAL TRANSITION; BRONCHIOLITIS OBLITERANS SYNDROME; DIFFERENTIAL EXPRESSION; INDUCED EMT; TGF-BETA; TRANSPLANTATION; HEART; CANCER; MECHANISMS; STRATEGIES;
D O I
10.1016/j.healun.2016.03.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lung transplantation (LT) has proven to be successful in carefully selected individuals with end-stage lung disease. However, long-term graft survival post-LT is often hindered by the development of the bronchiolitis obliterans syndrome (BOS). Because BOS represents is a major problem for all LT centers, early identification and prediction of progressive loss of lung function is a major goal. MicroRNAs (miRNAs) play a major role in regulating many cellular functions, including epithelial-to-mesenchymal transition. miRNAs are emerging not only as biomarkers but also as potential therapy. The recognized importance of injured human bronchial epithelium in lung allograft dysfunction indicates that there is a need for research into the potential role of miRNAs. In this we review we summarize published findings in miRNAs implicated in lung and other types of allograft dysfunction and their role in maintaining the phenotype of epithelial cells after transplant injury. We also address potential clinical interventions that involve manipulating miRNA expression that may promote long-term airway integrity and graft survival. (C) 2016 International Society for Heart and Lung Transplantation. All rights reserved.
引用
收藏
页码:550 / 559
页数:10
相关论文
共 50 条
  • [31] LYMPHOCYTIC BRONCHITIS AND LUNG ALLOGRAFT-REJECTION
    HRUBAN, RH
    BESCHORNER, WE
    HUTCHINS, GM
    TRANSPLANTATION, 1990, 50 (04) : 723 - 723
  • [32] Paying a toll for acute lung allograft rejection
    Belperio, JA
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (06) : 623 - 624
  • [33] DIAGNOSIS AND MANAGEMENT OF LUNG ALLOGRAFT-REJECTION
    LAWRENCE, EC
    CLINICS IN CHEST MEDICINE, 1990, 11 (02) : 269 - 278
  • [34] Markers of rejection of a lung allograft: state of the art
    de Silva, Tharushi
    Voisey, Joanne
    Hopkins, Peter
    Apte, Simon
    Chambers, Daniel
    O'Sullivan, Brendan
    BIOMARKERS IN MEDICINE, 2022, 16 (06) : 483 - 498
  • [35] A perspective on radiation therapy for lung allograft rejection
    Garrity, ER
    CHEST, 1996, 109 (05) : 1136 - 1138
  • [36] Extracorporeal photopheresis for the management of lung allograft rejection
    Witt, Chad A.
    Hachem, Ramsey R.
    CLINICAL TRANSPLANTATION, 2017, 31 (10)
  • [37] The Pathology of Lung Allograft Rejection: A Concise Review
    Roden, Anja
    Tazelaar, Henry
    TURKISH THORACIC JOURNAL, 2012, 13 (03) : 122 - 129
  • [38] miRNA dysregulation in chronic lung allograft rejection
    Morbini, P.
    Rossi, E.
    Inghilleri, S.
    Piloni, D.
    Zorzetto, M.
    Calabrese, F.
    Meloni, F.
    VIRCHOWS ARCHIV, 2017, 471 : S38 - S38
  • [39] A model of chronic lung allograft rejection in the rat
    Jungraithmayr, W.
    Vogt, P.
    Inci, I.
    Hillinger, S.
    Arni, S.
    Korom, S.
    Weder, W.
    EUROPEAN RESPIRATORY JOURNAL, 2010, 35 (06) : 1354 - 1363
  • [40] IMMUNOLOGICAL MONITORING OF LUNG ALLOGRAFT-REJECTION
    STIKHANOVSKAYA, LD
    VESTNIK AKADEMII MEDITSINSKIKH NAUK SSSR, 1990, (08): : 54 - 60